{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:05:46Z","timestamp":1785323146940,"version":"3.55.0"},"reference-count":25,"publisher":"Baskent University","issue":"Supp 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.mesot2025.p132","type":"journal-issue","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:45:11Z","timestamp":1785239111000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Zhang JLH, Appelman-Dijkstra NM, Schepers A. Parathyroid allotransplantation: a systematic review. Med Sci (Basel). 2022;10(1)doi:10.3390\/medsci10010019","DOI":"10.3390\/medsci10010019"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Devon K, Tinckam K, Humar A, et al. Successful deceased donor parathyroid allotransplantation: a novel approach in a patient with severe refractory hypoparathyroidism after thyroidectomy for thyroid cancer. Thyroid. 2024;34(8):1058-1061. doi:10.1089\/thy.2024.0115","DOI":"10.1089\/thy.2024.0115"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Nawrot I, Wozniewicz B, Tolloczko T, et al. Allotransplantation of cultured parathyroid progenitor cells without immunosuppression: clinical results. Transplantation. 2007;83(6):734-740. doi:10.1097\/01.tp.0000258601.17505.9d","DOI":"10.1097\/01.tp.0000258601.17505.9d"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Shi X, Lv J, Han W, et al. What is the impact of human leukocyte antigen mismatching on graft survival and mortality in renal transplantation? A meta-analysis of 23 cohort studies involving 486,608 recipients. BMC Nephrol. 2018;19(1):116. doi:10.1186\/s12882-018-0908-3","DOI":"10.1186\/s12882-018-0908-3"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Poli F, Mascaretti L, Pappalettera M, Scalamogna M, Bernardi L, Sirchia G. HLA-DRB1 compatibility in cadaver kidney transplantation: correlation with graft survival and function. Transpl Int. 1995;8(2):91-95. doi:10.1007\/BF00344417","DOI":"10.1007\/BF00344417"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Ichikawa Y, Fujimoto N, Hashimoto M, et al. Long-term graft survival rate of zero-mismatch kidney transplants for HLA-DRB1. Transpl Int. 1994;7 Suppl 1:S281-285. doi:10.1111\/j.1432-2277.1994.tb01367.x","DOI":"10.1111\/j.1432-2277.1994.tb01367.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Kaies Ibrahim Elsayed Ali H, Mohamed M, Briggs D, Krishnan N. MO994: Impact of HLA-A, B DR and DQ on renal transplant outcomes in the tacrolimus\/MMF era: an artificial intelligence approach. Nephrol Dial Transplant. 2022;37(Supplement_3):gfac087.052. doi:10.1093\/ndt\/gfac087.052","DOI":"10.1093\/ndt\/gfac087.052"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transpl Int. 2011;24(11):1084-1093. doi:10.1111\/j.1432-2277.2011.01312.x","DOI":"10.1111\/j.1432-2277.2011.01312.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Campos J, Quijano Y, Franco A, et al. Beneficial effects of HLA class II incompatibility in living donor liver transplantation. Transplant Proc. 2003;35(5):1888-1891. doi:10.1016\/s0041-1345(03)00637-7","DOI":"10.1016\/S0041-1345(03)00637-7"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Malfait T, Emonds MP, Daniels L, Nagler EV, Van Biesen W, Van Laecke S. HLA class II antibodies at the time of kidney transplantation and cardiovascular outcome: a retrospective cohort study. Transplantation. 2020;104(4):823-834. doi:10.1097\/TP.0000000000002889","DOI":"10.1097\/TP.0000000000002889"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Geneugelijk K, Niemann M, Drylewicz J, et al. PIRCHE-II is related to graft failure after kidney transplantation. Front Immunol. 2018;9:321. doi:10.3389\/fimmu.2018.00321","DOI":"10.3389\/fimmu.2018.00321"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Bekbolsynov D, Mierzejewska B, Borucka J, et al. Low hydrophobic mismatch scores calculated for HLA-A\/B\/DR\/DQ loci improve kidney allograft survival. Front Immunol. 2020;11:580752. doi:10.3389\/fimmu.2020.580752","DOI":"10.3389\/fimmu.2020.580752"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Tafulo S, Malheiro J, Santos S, et al. HLA class II eplet mismatch load improves prediction of dnDSA development after living donor kidney transplantation. Int J Immunogenet. 2021;48(1):1-7. doi:10.1111\/iji.12519","DOI":"10.1111\/iji.12519"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Goncu B, Salepcioglu Kaya H, Yucesan E, Ersoy YE, Akcakaya A. Graft survival effect of HLA-A allele matching parathyroid allotransplantation. J Investig Med. 2021;69(3):785-788. doi:10.1136\/jim-2020-001648","DOI":"10.1136\/jim-2020-001648"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Goncu B, Yucesan E, Ersoy YE, Aysan ME, Ozten Kandas N. HLA-DR, -DP, -DQ expression status of parathyroid tissue as a potential parathyroid donor selection criteria and review of literature. Hum Immunol. 2022;83(2):113-118. doi:10.1016\/j.humimm.2021.12.003","DOI":"10.1016\/j.humimm.2021.12.003"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Goncu B, Yucesan E, Aysan E, Kandas NO. HLA class I expression changes in different types of cultured parathyroid cells. Exp Clin Transplant. 2022;20(9):854-862. doi:10.6002\/ect.2018.0388","DOI":"10.6002\/ect.2018.0388"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Chinn IK, Markert ML. Induction of tolerance to parental parathyroid grafts using allogeneic thymus tissue in patients with DiGeorge anomaly. J Allergy Clin Immunol. 2011;127(6):1351-1355. doi:10.1016\/j.jaci.2011.03.033","DOI":"10.1016\/j.jaci.2011.03.033"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Goncu B, Yucesan E, Salepcioglu Kaya H, Kazancioglu R, Ersoy YE, Akcakaya A. The challenge of preoperative panel reactive antibody positivity in parathyroid transplantation. Exp Clin Transplant. 2024;22(Suppl 1):233-242. doi:10.6002\/ect.MESOT2023.P59","DOI":"10.6002\/ect.MESOT2023.P59"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Barczynski M, Golkowski F, Nawrot I. Parathyroid transplantation in thyroid surgery. Gland Surg. 2017;6(5):530-536. doi:10.21037\/gs.2017.06.07","DOI":"10.21037\/gs.2017.06.07"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Yucesan E, Basoglu H, Goncu B, Akbas F, Ersoy YE, Aysan E. Microencapsulated parathyroid allotransplantation in the omental tissue. Artif Organs. 2019;43(10):1022-1027. doi:10.1111\/aor.13475","DOI":"10.1111\/aor.13475"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Ali A, Al-Kaisi A, Ali I. Clinical relevance of pretransplant testing for anti-human leukocyte antigen antibodies in Iraqi renal transplant patients. Exp Clin Transplant. 2019;17(Suppl 1):164-168. doi:10.6002\/ect.MESOT2018.P40","DOI":"10.6002\/ect.MESOT2018.P40"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Meneghini M, Tambur AR. HLA (emphasis on DQ) compatibility for longer allograft survival in pediatric transplantation: modern evidence and challenges. Pediatr Transplant. 2024;28(1):e14606. doi:10.1111\/petr.14606","DOI":"10.1111\/petr.14606"},{"key":"ref22","unstructured":"23. Goncu B, G\u00fcrol AO. Tissue-specific immunity for transplantable endocrine glands in the context of HLA expression. In: G\u00f6nen S, ed. Human Leukocyte Antigens - Updates and Advances. IntechOpen; 2023."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Niemann M, Matern BM, Spierings E. PIRCHE-II risk and acceptable mismatch profile analysis in solid organ transplantation. Methods Mol Biol. 2024;2809:171-192. doi:10.1007\/978-1-0716-3874-3_12","DOI":"10.1007\/978-1-0716-3874-3_12"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Guell-Alonso R, Cabrera-Perez R, Vives J. Immunocompatibility in transplantation: adapting to a changing therapeutic landscape. Front Immunol. 2025;16:1648534. doi:10.3389\/fimmu.2025.1648534","DOI":"10.3389\/fimmu.2025.1648534"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:43:13Z","timestamp":1785321793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2026\/24\/6\/2\/434\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"Supp 2","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2025.p132","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}